[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
3. Miller TR, Pinkus E, Dehdashti F, Grigsby PW: Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med; 2003 Feb;44(2):192-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with cervical cancer, it is important to estimate prognosis at the time of diagnosis.
  • This study using PET with (18)F-FDG was undertaken to determine whether a simple and fast visual analysis of characteristics of the primary tumor before initiation of treatment could achieve this goal.
  • METHODS: Forty-seven patients with cervical cancer who were to be treated by combined radiation therapy and chemotherapy were imaged before beginning treatment.
  • Three observers then independently graded the primary tumor for size (0 = small, 1 = moderate, 2 = large), shape (0 = spherical, 1 = nonspherical), heterogeneity of uptake (0 = none, 1 = moderate, 2 = marked), and presence of lymph nodes (0 = none, 1 = pelvic, 2 = paraaortic, 3 = distant).
  • Evaluation of lymph nodes alone was compared with the grading of tumor characteristics.
  • Evaluation of lymph nodes also separated the groups, but not as well as did visual analysis alone.
  • CONCLUSION: A simple, rapid, and highly reproducible system is described for visual grading of characteristics of the primary tumor in patients with cervical cancer at the time of diagnosis.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / secondary. Fluorodeoxyglucose F18. Tomography, Emission-Computed / methods. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Observer Variation. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Severity of Illness Index. Single-Blind Method. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12571208.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA85797
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. Oh KC, Zang DY: Primary non-Hodgkin's lymphoma of the bladder with bone marrow involvement. Korean J Intern Med; 2003 Mar;18(1):40-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the bladder with bone marrow involvement.
  • Involvement of the lower urinary tract by advanced non-Hodgkin's lymphoma (NHL) has been reported in up to 13% of cases, but primary NHL of the urinary bladder is very rare.
  • Cystoscopy revealed an edematous broad-based mass on the left lateral wall of the bladder, and transurethral biopsy showed NHL, diffuse large B-cell type.
  • Abdomino-pelvic CT scan demonstrated left-side hydronephrosis and hydroureter with left proximal ureter infiltration and thickening of the left lateral wall of the bladder with perivesical fat infiltration without lymph node enlargement.
  • The lesions of the bladder and left urinary tract were nearly completely regressed after two cycles of systemic cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy with simultaneous restoration of urinary function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Bone Neoplasms / secondary. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / pathology. Prednisone / administration & dosage. Urinary Bladder Neoplasms / pathology. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Biopsy, Needle. Cystoscopy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome. Urodynamics

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12760267.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC4531605
  •  go-up   go-down


5. Albores-Saavedra J, Martinez-Benitez B, Luevano E: Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol; 2008 Jul;27(3):333-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis.
  • We report 5 polypoid high-grade neuroendocrine carcinomas of the uterus, 2 small cell carcinomas of the endometrium, and 3 large cell neuroendocrine carcinomas, 2 from the cervix and 1 from the endometrium.
  • The 2 small cell carcinomas of the endometrium arose from and were confined to endometrial polyps, one of which also showed foci of endometrioid adenocarcinoma.
  • The 3 large cell neuroendocrine carcinomas, 2 from the cervix and 1 from the endometrium, were polypoid but did not originate in polyps.
  • All 5 patients were treated by radical hysterectomy and 4 received adjuvant chemotherapy.
  • Only 2 patient had pelvic lymph node metastasis.
  • All patients are alive and disease-free from 9 months to 7 years after treatment (mean survival, 47 months).
  • Two small cell carcinomas and 2 large cell neuroendocrine carcinomas accumulated p53 protein.
  • Two small cell carcinomas and 2 large cell neuroendocrine carcinomas expressed p16.
  • Our findings suggest that stage of disease and a polypoid gross feature are the best predictors for outcome in small cell carcinomas and large cell neuroendocrine carcinomas of the uterus.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Endometrial Neoplasms / pathology. Neuroendocrine Tumors / pathology. Polyps / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580310.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Stein JP, Cai J, Groshen S, Skinner DG: Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol; 2003 Jul;170(1):35-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density.
  • PURPOSE: We evaluated the clinical outcomes and risk factors for progression in a large cohort of patients with lymph node metastases following en bloc radical cystectomy and bilateral pelvic lymphadenectomy.
  • MATERIALS AND METHODS: From July 1971 through December 1997, 1,054 patients underwent radical cystectomy and bilateral pelvic-iliac lymphadenectomy for high grade, invasive transitional cell carcinoma of the bladder.
  • Of these patients 244 (23%) with a median age of 66 years (range 36 to 90) had pathological lymph node metastases.
  • Overall 139 of the 244 patients (57%) received some form of chemotherapy.
  • At a median followup of greater than 10 years (range 0 to 28) outcomes data were analyzed in univariate analysis according to tumor grade, carcinoma in situ, primary bladder tumor stage, pathological subgroups, total number of lymph nodes removed and involved with tumor, and lymph node density (total number of positive lymph nodes/total number removed).
  • In addition, the form of urinary diversion and the administration of chemotherapy were also evaluated.
  • RESULTS: The incidence of positive lymph nodes increased with higher p stage and pathological subgroups.
  • Of 669 patients 75 (11%) with organ confined primary tumors and 169 of 385 (44%) with extravesical tumor extension had involved lymph nodes.
  • The median number of lymph nodes removed in the 244 lymph node positive cases was 30 (range 1 to 96), while the median number of positive lymph nodes was 2 (range 1 to 63).
  • Overall recurrence-free survival at 5 and 10 years for the 244 patients with lymph node positive disease was 35% and 34%, respectively.
  • Patients with lymph node positive disease and an organ confined primary bladder tumor had significantly improved 10-year recurrence-free survival compared with those with extravesical tumor extension (44% vs 30%, p = 0.003).
  • The total number of lymph nodes removed at surgery was also prognostic.
  • Patients with 15 or less lymph nodes removed had 25% 10-year recurrence-free survival compared with 36% when greater than 15 lymph nodes were removed.
  • Recurrence-free survival at 10 years for patients with 8 or less positive lymph nodes was significantly higher than in those with greater than 8 positive lymph nodes (40% vs 10%, p <0.001).
  • The novel concept of lymph node density was also a significant prognostic factor.
  • Patients with a lymph node density of 20% or less had 43% 10-year recurrence-free survival compared with only 17% survival at 10 years when lymph node density was greater than 20% (p <0.001).
  • On multivariate analysis the total number of lymph nodes involved, pathological subgroups of the primary bladder tumor, lymph node density and adjuvant chemotherapy remained significant and independent risk factors for recurrence-free and overall survival.
  • CONCLUSIONS: Patients with lymph node tumor involvement following radical cystectomy may be stratified into high risk groups based on the primary bladder tumor, pathological subgroup, number of lymph nodes removed and total number of lymph nodes involved.
  • Lymph node density, which is a novel prognostic indicator, may better stratify lymph node positive cases because this concept collectively accounts for the total number of positive lymph nodes (tumor burden) and the total number of lymph nodes removed (extent of lymphadenectomy).
  • Future staging systems and the application of adjuvant therapies in clinical trials should consider applying lymph node density to help standardize this high risk group of patients following radical cystectomy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / surgery. Cystectomy. Lymph Node Excision. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Regression Analysis. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12796639.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Seki H, Takada T, Sodemoto T, Hoshino H, Saitoh K, Uekusa T: A young woman with clear cell adenocarcinoma of the uterine cervix. Int J Clin Oncol; 2003 Dec;8(6):399-404
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A young woman with clear cell adenocarcinoma of the uterine cervix.
  • In May 1999, an 18-year-old woman visited a physician because of vaginal bleeding and the excretion of large clots from the vagina.
  • The cytological finding of the uterine cervix was class V, and the histological diagnosis by punch biopsy was clear cell adenocarcinoma (CCAC) of the uterine cervix.
  • The patient initially received neoadjuvant chemotherapy (NAC) with intraarterial injections of 8 mg/m(2) of mitomycin, 270 mg/m(2) of etoposide, and 380 mg/m(2) of carboplatin.
  • A radical abdominal hysterectomy and pelvic lymphadenectomy were performed on October 12.
  • The patient was discharged from our hospital without any postoperative chemotherapy or radiation therapy.
  • While there were similarities between the patients in the two countries in the patients' pattern of growth and the poor prognosis of the tumors, there was a significant difference between the countries in the patients' history of diethylstilbestrol (DES) exposure.
  • These results suggest that menarche and menopause may play roles in promoting carcinogenesis, or alternatively, that a subpopulation of women are subject to genetic or exogenous risk factors other than DES.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adolescent. Age of Onset. Carboplatin / administration & dosage. Carcinogens / adverse effects. Diethylstilbestrol / adverse effects. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Japan. Lymph Node Excision. Mitomycin / administration & dosage. Neoadjuvant Therapy. Netherlands. Prognosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Clin Oncol. 2004 Jun;9(3):213; author reply 213-4 [15221610.001]
  • (PMID = 14663645.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinogens; 50SG953SK6 / Mitomycin; 6PLQ3CP4P3 / Etoposide; 731DCA35BT / Diethylstilbestrol; BG3F62OND5 / Carboplatin
  •  go-up   go-down


8. Malzoni M, Spina V, Perniola G, Aleandri V, Mossa B, Iuele T, Imperato F: Laparoscopic surgery in treatment of stage IIb cervical cancer after neoadjuvant chemotherapy. A case report and review of the literature. Eur J Gynaecol Oncol; 2003;24(5):393-7
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery in treatment of stage IIb cervical cancer after neoadjuvant chemotherapy. A case report and review of the literature.
  • BACKGROUND: A detailed operative procedure of laparoscopic radical hysterectomy (type III) with pelvic and aortic lymphadenectomy after neoadjuvant chemoterapy in treatment of Stage IIb cervical cancer is described.
  • CASE REPORT: A 50-year-old patient with Stage IIb squamous cell carcinoma of the uterine cervix, who initially was not surgically resectable, received three courses of neoadjuvant chemotherapy that included ifosfamide 5 g/m2, cisplatin 50 mg/m2 and paclitaxel 175 mg/m2 (TIP).
  • Following a partial clinical response to chemotherapy, the patient underwent laparoscopic type III radical hysterectomy with bilateral salpingo-oophorectomy and pelvic and paraaortic lymphadenectomy.
  • The surgical procedure lasted 250 minutes.
  • The number of dissected lymph nodes was 48:29 pelvic and 19 paraaortic nodes.
  • The patient also underwent adjuvant radiation therapy.
  • CONCLUSIONS: This experience suggests that such a surgical procedure is safe.
  • Large studies with long term follow-up are needed to confirm that this approach may be proposed as an alternative to conventional surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Laparoscopy. Neoadjuvant Therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14584654.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


9. Okudaira T, Nagasaki A, Miyagi T, Nakazato T, Taira N, Kudaka W, Maehama T, Takasu N: [Primary diffuse large B-cell lymphoma of the uterine cervix--a case report]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1423-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell lymphoma of the uterine cervix--a case report].
  • Primary malignant lymphoma of the female genital tract is an extremely rare clinical entity.
  • We report a case of primary non-Hodgkin lymphoma of the uterine cervix.
  • Involvement of pelvic lymph nodes was also observed.
  • No other lesions were detected by the whole-body computed tomography, gallium scintigraphy, and bone marrow examination.
  • A diagnosis of diffuse large B-cell lymphoma of the uterine cervix, clinical stage IIE was made.
  • The patient was treated with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone(CHOP)chemotherapy followed by the involved field irradiation.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Combined Modality Therapy. Female. Humans


10. Dos Santos L, Mok E, Iasonos A, Park K, Soslow RA, Aghajanian C, Alektiar K, Barakat RR, Abu-Rustum NR: Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol; 2007 May;105(2):321-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature.
  • OBJECTIVES: Malignant transformation of mature cystic teratomas is rare, with squamous cell carcinoma being the most common type.
  • We conducted this study to review our experience with this disease and describe our current treatment modality.
  • METHODS: During a 22-year period (1983-2005), we identified 17 women treated for squamous cell carcinoma arising in a mature cystic teratoma of the ovary.
  • All patients underwent surgery, with positive lymph nodes noted in 0 of 10 cases that included lymph node dissection.
  • Ten patients received adjuvant treatment-6 with chemotherapy and 4 with chemoradiation.
  • Six patients had recurrent disease in the pelvis after adjuvant treatment.
  • The 4 patients with stages IA-IIB disease treated with adjuvant platinum-based chemotherapy and radiation survived at 12-56 months' follow-up.
  • CONCLUSIONS: Squamous carcinomas arising in mature cystic teratomas are commonly large ovarian tumors that occur in perimenopausal women and often present as an incidental pathologic finding.
  • While the prognosis seems highly dependent on surgical stage, there is a lack of consensus in the literature regarding adjuvant treatment.
  • Platinum-based chemotherapy with pelvic radiation may be a reasonable adjuvant therapy for early-stage disease.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Lymph Nodes / pathology. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies


11. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol; 2006 Dec;176(6 Pt 1):2414-22; discussion 2422
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
  • PURPOSE: We present the characteristics and outcomes of a large, contemporary, consecutive series of patients treated with radical cystectomy and pelvic lymphadenectomy for transitional cell carcinoma of the bladder.
  • MATERIALS AND METHODS: We developed a multi-institutional database and collected retrospective and prospective data on 888 consecutive patients with bladder transitional cell carcinoma who were treated with radical cystectomy and pelvic lymphadenectomy at 3 academic centers in the United States between 1984 and 2003.
  • RESULTS: Of the patients 25% had extravesical tumor extension with negative lymph nodes and 23% had lymph node metastasis.
  • The rate of lymph node involvement increased with advancing pathological stage.
  • Mean recurrence-free and bladder cancer specific survival +/- SE was 58% +/- 2% and 66% +/- 2% at 5 years, respectively.
  • On preoperative multivariate analysis clinical tumor stage and neoadjuvant systemic chemotherapy were associated with cancer recurrence, while more advanced age, clinical tumor stage and preoperative carcinoma in situ were associated with bladder cancer specific mortality.
  • On postoperative multivariate analysis pathological tumor stage, lymph node metastasis, lymphovascular invasion, adjuvant radiotherapy and adjuvant chemotherapy were associated with cancer recurrence, while higher pathological tumor stage, more advanced age, lymph node metastasis, lymphovascular invasion and adjuvant radiotherapy were associated with disease specific survival.
  • Patients with metastasis to regional lymph nodes (pT any N1-3) were at significantly higher risk for bladder cancer recurrence and death than patients with extravesical tumor extension (pT3N0), who in turn were at significantly higher risk than patients with organ confined disease (pT2 N0 or less).
  • CONCLUSIONS: The results of this large, contemporary, multi-institutional series show that radical cystectomy and pelvic lymphadenectomy provide durable local control and disease specific survival in patients with localized invasive transitional cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Lymph Node Excision. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Radiotherapy, Adjuvant. Regression Analysis


12. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG: Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol; 2006 Aug;176(2):486-92; discussion 491-2
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era.
  • PURPOSE: We studied the effect of radical cystectomy for transitional cell carcinoma of the bladder on survival and failure patterns when the 2 surgical standards cystectomy and neobladder were combined, when possible.
  • MATERIALS AND METHODS: A consecutive series of patients undergoing radical cystectomy with pelvic lymph node dissection for transitional cell carcinoma of the bladder with curative intent was analyzed.
  • Patients with neoadjuvant radiotherapy/chemotherapy were excluded.
  • Positive lymph nodes were present in 143 patients (18%).
  • Local and distant failure rates were 4% and 9.5% for organ confined tumors, 15.9% and 19.2% for nonorgan confined tumors, and 20.4% and 45.1% in patients with positive lymph nodes, respectively.
  • CONCLUSIONS: In patients with organ confined, lymph node negative transitional cell carcinoma excellent survival data can be achieved as long as the tumor is limited to the inner half of the detrusor.
  • These data on a large group of patients support early aggressive surgical management for invasive bladder cancer.
  • The results of this surgery only series may serve as a reference for other treatment modalities for bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Urinary Bladder Neoplasms / surgery. Urinary Diversion

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Urol. 2007 Mar;4(3):126-7 [17290247.001]
  • [CommentIn] Eur Urol. 2008 Jan;53(1):208-9 [18240412.001]
  • (PMID = 16813874.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Steed HL, Pearcey RG, Capstick V, Honore LH: Invasive squamous cell carcinoma of the vagina during pregnancy. Obstet Gynecol; 2002 Nov;100(5 Pt 2):1105-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive squamous cell carcinoma of the vagina during pregnancy.
  • BACKGROUND: Squamous cell carcinoma of the vagina in pregnancy is rare.
  • CASE: A 28-year-old primigravida with antepartum bleeding at 20 weeks' gestation was diagnosed with squamous cell carcinoma after biopsy of a vaginal mass.
  • The histology revealed an invasive grade 3 squamous cell carcinoma of large-cell, nonkeratinizing type.
  • The patient declined pregnancy termination and immediate radiation treatment.
  • A decision was made in consultation with the neonatal unit to deliver her at 32 weeks' gestation.
  • After corticosteroid treatment, she was delivered by cesarean delivery.
  • Positive pelvic lymph nodes were noted at surgery.
  • Postoperatively, she received external beam radiation and brachytherapy and concurrent cisplatin chemotherapy.
  • CONCLUSION: This case emphasizes the importance of a thorough pelvic examination to assess the vaginal walls and cervix at the first prenatal visit and with any antepartum bleeding episode.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Pregnancy Complications, Neoplastic / pathology. Pregnancy Complications, Neoplastic / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adult. Brachytherapy. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Pregnancy. Radiotherapy Dosage


14. Cantú de León D, Pérez Montiel D, Chanona Vilchis J: Primary malignant lymphoma of uterine cervix. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):923-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of uterine cervix.
  • Primary malignant lymphoma of the uterine cervix is a rare disease.
  • Malignant lymphoma can be clinically and histopathologically misdiagnosed for the infrequent presentation in this are.
  • A biopsy was performed and histopathological studies reported a large cell B lymphoma.
  • After the diagnosis CT abdominal, pelvic and thoracic scan was performed and shows infiltration to posterior bladder without evidence of disease in lymph nodes or another organ.
  • The patient was treated with chemotherapy and radiotherapy.
  • Six month after finish the treatment is well and free of disease.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681788.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Lal DR, Su WT, Wolden SL, Loh KC, Modak S, La Quaglia MP: Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg; 2005 Jan;40(1):251-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of multimodal treatment for desmoplastic small round cell tumors.
  • PURPOSE: Desmoplastic small round cell tumors (DSRCTs) are rare aggressive neoplasms that frequently present with large symptomatic intraabdominal masses.
  • We examined the effects of multimodal therapy including induction chemotherapy, aggressive surgical debulking, and external beam radiotherapy on patients with DSRCT.
  • Data were collected on patient demographics, presenting symptoms, tumor location and extent, treatment regimen, and overall survival.
  • Thirty-three (50%) had positive lymph nodes and 27 (41%) had distant parenchymal metastases at diagnosis.
  • Twenty-nine of these patients (44%) underwent induction chemotherapy (P6), surgical debulking, and radiotherapy.
  • Three-year survival was 55% in those receiving chemotherapy, surgery, and radiotherapy vs 27% when all 3 modalities were not used (P < .02).
  • CONCLUSIONS: Multimodal therapy results in improved survival in patients with DSRCT.
  • [MeSH-major] Sarcoma, Small Cell / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Abdominal Neoplasms / therapy. Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Pelvic Neoplasms / pathology. Pelvic Neoplasms / surgery. Pelvic Neoplasms / therapy. Radiotherapy. Surgical Procedures, Operative. Survival Analysis. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery. Testicular Neoplasms / therapy. Thoracic Neoplasms / pathology. Thoracic Neoplasms / surgery. Thoracic Neoplasms / therapy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868593.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Mohile SG, Schleicher L, Petrylak DP: Treatment of metastatic urachal carcinoma in an elderly woman. Nat Clin Pract Oncol; 2008 Jan;5(1):55-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic urachal carcinoma in an elderly woman.
  • On physical examination, she had a palpable pelvic mass.
  • Imaging revealed a large pelvic mass situated on the dome of the bladder, extending from the urachus, without evidence of other sites of metastases.
  • No adjuvant therapy was administered.
  • Repeat imaging obtained 3 months after resection revealed a large left pelvic mass consistent with recurrence.
  • INVESTIGATIONS: Physical examination, pelvic and complete lymph-node examination, laboratory tests, urine analysis, CT scan of the abdomen and pelvis, chest X-ray, bone scan, cystoscopy, histologic examination of tumor morphology, and MRI of the abdomen and pelvis.
  • MANAGEMENT: Surgical excision combined with cystectomy and pelvic lympadenectomy, chemotherapy with 5-fluorouracil, leucovorin, and irinotecan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / secondary. Cystectomy. Lymph Node Excision. Pelvic Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097457.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


17. Torres MA, Jhingran A, Thames HD Jr, Levenback CF, Bodurka DC, Ramondetta LM, Eifel PJ: Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys; 2008 Jan 1;70(1):118-25
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.
  • PURPOSE: To compare the treatment and outcomes of cervical cancer patients treated with concurrent chemoradiotherapy (CT-RT) in a multi-institutional trial or as standard care.
  • Of the 302 patients, 76 were treated using cisplatin and 5-fluorouracil (C/F) on Radiation Therapy Oncology Group protocol 90-01 (CT-RT(90-01)); 226 underwent CT-RT as standard care with either C/F [CT-RT(SC(C/F)); n = 115] or weekly cisplatin [CT-RT(SC(WC)); n = 111).
  • During treatment, CT-RT(SC(C/F)) patients experienced more Grade 2-3 neutropenia and were, therefore, less likely to receive 200 mg/m(2) cisplatin than were either CT-RT(SC(WC)) or CT-RT(90-01) patients (52% vs. 77% vs. 85%, respectively; p <0.001).
  • On multivariate analysis, C/F chemotherapy, cisplatin dose >or=200 mg/m(2), Stage I-II disease, and negative pelvic lymph nodes were independent predictors of improved disease-specific survival.
  • CONCLUSIONS: Even within a large comprehensive cancer center, the high rates of chemotherapy completion achieved on a multi-institutional trial can be difficult to reproduce in standard practice.
  • Although C/F toxicity was greater in the standard care patients, their outcomes were similar to those of patients treated with C/F on Radiation Therapy Oncology Group protocol 90-01.
  • [MeSH-major] Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leukopenia / etiology. Middle Aged. Multivariate Analysis. Neutropenia / etiology. Proportional Hazards Models. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869451.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Coulibalya B, Liprandia A, Le Hémon A, Fernandez C, Hardwigsen J, Berthet B, Bouvier C: [Desmoplastic small round-cell tumor: two cases of diffuse abdominopelvic infiltration]. Gastroenterol Clin Biol; 2008 Mar;32(3):278-81
Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoplastic small round-cell tumor: two cases of diffuse abdominopelvic infiltration].
  • Desmoplastic small round-cell tumors are a rare malignant tumor that affects male children and young adults.
  • It frequently presents as a large abdominal mass with widespread peritoneal involvement at diagnosis.
  • We report two cases of desmoplastic small round-cell tumors, with diffuse infiltration in the abdomen and pelvis in two adult caucasian males.
  • The first case-report is a middle-aged man and the second a young adult man with early recurrence and diffuse metastatic lymph nodes.
  • The prognosis remains poor and leads to death in most cases, despite surgical resection, radiotherapy and high-dose chemotherapy.
  • [MeSH-major] Abdominal Neoplasms / pathology. Fibromatosis, Aggressive / pathology. Pelvic Neoplasms / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Fatal Outcome. Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663785.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Linassier C, Desablens B, Lefrancq T, Le Prise PY, Harousseau JL, Jacob C, Gandhour C, Haillot O, Lucas V, Leloup R, Escoffre M, Colombat P, Tabuteau S, GOELAMS Study Group: Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. Clin Lymphoma; 2002 Dec;3(3):167-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group.
  • Sixteen patients with aggressive primary testicular involvement were analyzed separately from a prospective multicenter series of 494 patients with stage I/II aggressive nonlymphoblastic lymphoma.
  • The treatment strategy included 3 cycles of anthracycline-based chemotherapy followed by regional radiation therapy on inguinal, iliac, and para-aortic lymph nodes and central nervous system (CNS) prophylaxis by intrathecal chemotherapy and brain irradiation.
  • Chemotherapy was stratified by age group.
  • Patients aged 18-60 years received the Groupe Ouest Est d'Etude des Leucemies Aigues et Maladies du Sang (GOELAMS) 02 protocol: 3 monthly cycles of VCAP (vindesine 3 mg/m2 day 1, doxorubicin 80 mg/m2 day 2, cyclophosphamide 1500 mg/m2 day 2, and prednisone 80 mg/m2 days 1-5).
  • The histological subtypes were diffuse large-cell lymphoma in all cases.
  • One patient died from septic shock during the last course of chemotherapy.
  • Relapse occurred in extranodal sites in 4 cases and in abdominal lymph nodes in the last case.
  • This is the first report of a prospective study in which treatment of testicular non-Hodgkin's lymphoma was precisely defined at diagnosis.
  • Compared to other series, a combination of orchiectomy with 3 cycles of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone)-derived chemotherapy, regional radiation therapy, and CNS prophylaxis seems to improve prognosis.
  • The improvement in prognosis seemed to be due in part to irradiation, including the pelvic and lomboaortic lymphatic areas, and in part to CNS prophylaxis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Brain / radiation effects. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Epirubicin / therapeutic use. Humans. Lymph Nodes / pathology. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Prospective Studies. Recurrence. Time Factors. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Lymphoma. 2002 Dec;3(3):173-4 [12521395.001]
  • (PMID = 12521394.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEV protocol; CHOP protocol
  •  go-up   go-down


21. Crowley C, Winship AZ, Hawkins MA, Morris SL, Leslie MD: Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation? Clin Oncol (R Coll Radiol); 2009 Jun;21(5):376-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Chemoradiation is the standard of care for the treatment of anal canal cancer, with surgery reserved for salvage.
  • For tumours with uninvolved inguinal nodes, it is standard to irradiate the inguinal nodes prophylactically, resulting in large field sizes, which contribute to acute and late toxicity.
  • MATERIALS AND METHODS: Between August 1998 and August 2004, 30 patients with biopsy-proven squamous cell anal canal cancer were treated with chemoradiation using one phase of treatment throughout.
  • A three-field beam arrangement was used without attempting to treat the draining inguinal lymph nodes prophylactically.
  • Concomitant chemotherapy was delivered with the radiation using mitomycin-C 7-12mg/m(2) on day 1 and protracted venous infusional 5-fluorouracil 200mg/m(2)/day throughout radiotherapy.
  • RESULTS: All patients had clinically and radiologically uninvolved inguinal and pelvic nodes and all had primary lesions that were T3 or less.
  • CONCLUSIONS: This single-centre retrospective study supports the treatment for selected cases of anal canal cancer with smaller than standard radiation fields, avoiding prophylactic inguinal nodal irradiation.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Lymphatic Irradiation. Radiation Injuries / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Female. Humans. Inguinal Canal. Male. Middle Aged. Patient Compliance. Pelvis. Radiation Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282157.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Huang J, Lin T, Liu H, Xu K, Zhang C, Jiang C, Huang H, Yao Y, Guo Z, Xie W: Laparoscopic radical cystectomy with orthotopic ileal neobladder for bladder cancer: oncologic results of 171 cases with a median 3-year follow-up. Eur Urol; 2010 Sep;58(3):442-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Radical cystectomy (RC) with pelvic lymph node dissection (PLND) is the standard treatment for muscle-invasive and high-risk non-muscle-invasive bladder cancer (BCa).
  • Large series with long-term oncologic data after laparoscopic RC (LRC) are rare.
  • Adjuvant chemotherapy was administered to patients with non-organ-confined disease or positive lymph nodes.
  • RESULTS AND LIMITATIONS: Most tumours were transitional cell carcinoma (TCC; 160, 93.6%).
  • There was involvement of the lymph nodes in 38 patients (22.2%).
  • The mean number of removed lymph nodes was 16 (5-46).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20554372.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Marnitz S, Köhler C, Füller J, Hinkelbein W, Schneider A: Uterus necrosis after radiochemotherapy in two patients with advanced cervical cancer. Strahlenther Onkol; 2006 Jan;182(1):45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A large body of literature concerning therapy-related acute and late morbidity is available.
  • Both patients were diagnosed with squamous cell cancer of the cervix FIGO stage IIB (T2b pN1 pM1 LYM G2) and FIGO IIIA (T3a pN1 M0 G2), respectively.
  • External-beam radiotherapy was applied in a 3-D-planned four-field technique, covering pelvic lymph nodes and primary tumor.
  • Patient #2 underwent 5 x 5 Gy brachytherapy covering the tumor.
  • Following chemoradiation, both patients developed pelvic pain and an elevation of C-reactive protein (CRP) in the presence of a normal leukocyte count.
  • CONCLUSION: In patients with persisting or incident pelvic pain, questionable findings in imaging techniques and/or elevated inflammation parameters following completion of chemoradiation for cervical cancer, differential diagnosis should include radiogenic necrosis of the uterus and other pelvic organs.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiation Injuries / etiology. Radiotherapy / adverse effects. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy. Uterus / pathology. Uterus / radiation effects
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Brachytherapy. Cervix Uteri / pathology. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Hysterectomy. Iridium Radioisotopes / therapeutic use. Laparoscopy. Middle Aged. Necrosis. Neoplasm Staging. Ovariectomy. Radiotherapy Dosage. Radiotherapy, Conformal. Time Factors


24. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol; 2001 Feb 01;19(3):666-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.
  • PURPOSE: To evaluate our long-term experience with patients treated uniformly with radical cystectomy and pelvic lymph node dissection for invasive bladder cancer and to describe the association of the primary bladder tumor stage and regional lymph node status with clinical outcomes.
  • PATIENTS AND METHODS: All patients undergoing radical cystectomy with bilateral pelvic iliac lymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July 1971 and December 1997, with or without adjuvant radiation or chemotherapy, were evaluated.
  • The 5- and 10-year recurrence-free survival for patients with organ-confined, lymph node-negative tumors was 92% and 86% for P0 disease, 91% and 89% for Pis, 79% and 74% for Pa, and 83% and 78% for P1 tumors, respectively.
  • Patients with muscle invasive (P2 and P3a), lymph node-negative tumors had 89% and 87% and 78% and 76% 5- and 10-year recurrence-free survival, respectively.
  • Patients with nonorgan-confined (P3b, P4), lymph node-negative tumors demonstrated a significantly higher probability of recurrence compared with those with organ-confined bladder cancers (P <.001).
  • A total of 246 patients (24%) had lymph node tumor involvement.
  • The 5- and 10-year recurrence-free survival for these patients was 35%, and 34%, respectively, which was significantly lower than for patients without lymph node involvement (P <.001).
  • Patients could also be stratified by the number of lymph nodes involved and by the extent of the primary bladder tumor (p stage).
  • Patients with fewer than five positive lymph nodes, and whose p stage was organ-confined had significantly improved survival rates.
  • The median time to recurrence among those patients in whom the cancer recurred was 12 months (range, 0.04 to 11.1 years).
  • In 234 patients (22%) there was a distant recurrence, and in 77 patients (7%) there was a local (pelvic) recurrence.
  • CONCLUSION: These data from a large group of patients support the aggressive surgical management of invasive bladder cancer.
  • Excellent long-term survival can be achieved with a low incidence of pelvic recurrence.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Morbidity. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11157016.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Liu LY, Zhang WZ, Guan J, Tong WC, Cai SX, Shen XB, Hou CC: [Lung cancer in pregnancy: report of two cases and review of literature]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Nov;33(11):844-8
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: the clinical presentations, diagnosis and treatment of 2 cases of lung cancer in pregnancy were reported, and related literatures were reviewed.
  • RESULTS: The first case was a 31-year-old pregnant woman at 34(th)-week gestation, who presented with right sided pleural effusion on a Chest X-ray film.
  • Biopsy of the right-supraclavicular lymph node was performed simultaneously, and histopathological examination showed metastatic large cell lung cancer.
  • Her respiratory condition worsened after the Caesarian section, and so mechanical ventilation, antibiotics and gefitinib were administered, but the treatment failed.
  • She died on the 28(th) day after Caesarian section.
  • PET showed right lung cancer with metastases to the pericardium, right pleura, liver and pelvic cavity.
  • Bronchoscopic biopsy showed small-cell lung cancer.
  • After pregnancy termination, the patient received 2 cycles of chemotherapy consisting of cisplatin and etoposide.
  • To improve the prognosis and prevent the metastasis to the fetus, systemic therapy should be considered, and meanwhile maternal advantage must be always weighed against possible embryo-fetal risks.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21211373.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down






Advertisement